The Spanish medtech also attracted the resources of co-lead investors Columbus Venture Partners and Mérieux Equity Partners
Spain’s medical scaleup deepull, a developer of cultivation-free diagnostic solutions for the rapid identification of pathogens, sepsis and acute infections, secured a Series C round of 50 million euros that Italian Panakès Partners, Columbus Venture Partners and Mérieux Equity Partners co-led. The company also attracted the resources of existing investors Asabys Partners, Innvierte-CDTI, We Venture Capital, UI Investissement, Axis-ICO, Aliath Bioventures, and Kurma Partners (press release).
The company is developing the test UllCORE BSI that would suit 95% of pathogens causing sepsis. The test extracts total microbial DNA from 8 ml of whole blood and provides 52 reportable results. The Deepull UllCORE analyser, a benchtop system with automation from sample to result designed to meet the needs of any hospital clinical laboratory, performs the test. The system received Innovative Device designation from the US Food and Drug Administration in December 2024. The company will invest the proceeds of the Series C round for finalising the clinical validation and accelerate the regulatory approval process of the UllCORE diagnostic system.
Jordi Carrera, deepull ceo, said: “This funding marks a major step forward as it prepares the company to complete clinical trials of its diagnostic system. With this support, we are ready to provide a revolutionary diagnostic solution to healthcare professionals and patients around the world.”
Rick Ivey, deepull chairman, added: “The strong support and oversubscription in this funding round reflect both the strength of our proprietary technology and its potential to redefine diagnostic standards.”
Alessio Piuma, a principal of Panakès Partners, explained: “We have long searched for an optimal solution in the field of sepsis and are extremely pleased to support deepull. Its promising UllCORE system has the potential to overcome the serious challenges doctors face in diagnosing sepsis.”
Jose Mesa, cio Partner of Columbus Venture Partners, said: “We are excited to support deepull’s vision as it transitions to commercialisation to impact the management of sepsis patients”.
Valérie Calenda, managing partner of Mérieux Equity Partners, pointed out: “We spotted the company at a very early stage a few years ago and are excited about its revolutionary technology that could radically transform the diagnosis and treatment of sepsis.
